Skip to main content

Medicine Matters rheumatology

David Jayne receives consultancy fees from Astra-Zeneca, BMS, Boehringer-Ingelheim, Chemocentryx, GSK, NICE, Novartis, Otsuka, Roche/Genentech, Takeda, UCB, and Vifor; lecture fees from Amgen and Vifor; board member at Aurinia; commercial research grants from GSK and Roche/Genentech; and non-commercial research grants from EU, MRC, NIHR, and Versus Arthritis.